The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL2104716     1-cyclopropyl-8- (difluoromethoxy)-7-[(1R)...

Synonyms: BMS-284756, AC1L3XUS, LS-140027, BMS-284756-01, Bms 284756, ...
This record was replaced with 124093.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of T-3811MEa

  • The objective of this study was to define the pharmacodynamic profile of BMS-284756 against Streptococcus pneumoniae [1].
  • The purpose of this study was to evaluate the pharmacodynamic profile and effectiveness of BMS-284756 for therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant S. pneumoniae (CRSP) [2].
  • Staphylococcus aureus mutants selected by BMS-284756 [3].
  • BMS-284756 inhibited approximately 60 to approximately 70% of the Enterococcus faecium (including vancomycin-resistant) strains and 90 to 100% of the Enterobacteriaceae strains and gastroenteric bacillary pathogens at the anticipated MIC susceptible breakpoint (</=4 microg/ml) [4].
  • The 50% protective doses of BMS-284756 against wild-type and mutant strains were 2.2 and 1.6 mg/kg of body weight/day, respectively, compared to the levofloxacin values of 16 and 71 mg/kg/day and moxifloxacin values of 4.7 and 61.6 mg/kg/day [5].

High impact information on T-3811MEa


Chemical compound and disease context of T-3811MEa


Biological context of T-3811MEa


Anatomical context of T-3811MEa

  • By histopathological evaluation, 6 h after the administration of T-3811ME (20 mg/kg as T-3811), the thickening of the cerebral meninx and the infiltration of neutrophils into the cerebral meninx were less severe in the treated group than in the nontreated group [13].
  • BMS 284756 penetrated well into inflamed meninges (44% +/- 11%) and produced good bactericidal activity (-0.82 +/- 0.22 Delta log(10) CFU/ml. h) in the treatment of experimental meningitis in rabbits due to a penicillin-sensitive strain [15].

Associations of T-3811MEa with other chemical compounds


Gene context of T-3811MEa

  • Although all quinolones selected, to a greater or lesser degree, for resistant clones with mutations usually in parC or gyrA, BMS-284756 tended to select for resistant clones at a lower rate than other quinolones studied [20].
  • Even against a penicillin- and quinolone-resistant strain, BMS 284756 showed good bactericidal activity (-0.52 +/- 0.12 Delta log(10) CFU/ml. h) [15].
  • In vitro susceptibility testing of BMS-284756 by the BSAC standardized disc testing method [21].

Analytical, diagnostic and therapeutic context of T-3811MEa


  1. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Nicolau, D.P., Mattoes, H.M., Banevicius, M., Xuan, D., Nightingale, C.H. Antimicrob. Agents Chemother. (2003) [Pubmed]
  2. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Rodriguez-Cerrato, V., Ghaffar, F., Saavedra, J., Michelow, I.C., Hardy, R.D., Iglehart, J., Olsen, K., McCracken, G.H. Antimicrob. Agents Chemother. (2001) [Pubmed]
  3. Staphylococcus aureus mutants selected by BMS-284756. Discotto, L.F., Lawrence, L.E., Denbleyker, K.L., Barrett, J.F. Antimicrob. Agents Chemother. (2001) [Pubmed]
  4. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Fung-Tomc, J.C., Minassian, B., Kolek, B., Huczko, E., Aleksunes, L., Stickle, T., Washo, T., Gradelski, E., Valera, L., Bonner, D.P. Antimicrob. Agents Chemother. (2000) [Pubmed]
  5. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Lawrence, L.E., Frosco, M., Ryan, B., Chaniewski, S., Yang, H., Hooper, D.C., Barrett, J.F. Antimicrob. Agents Chemother. (2002) [Pubmed]
  6. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart, S., Phillips, L., Ludwig, E.A., Russo, R., Gajjar, D.A., Bello, A., Ambrose, P.G., Costanzo, C., Grasela, T.H., Echols, R., Grasela, D.M. Antimicrob. Agents Chemother. (2004) [Pubmed]
  7. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities. Pérez-Vázquez, M., Román, F., Aracil, B., Cantón, R., Campos, J. Antimicrob. Agents Chemother. (2003) [Pubmed]
  8. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Rodriguez-Cerrato, V., McCoig, C.C., Saavedra, J., Barton, T., Michelow, I.C., Hardy, R.D., Bowlware, K., Iglehart, J., Katz, K., McCracken, G.H. Antimicrob. Agents Chemother. (2003) [Pubmed]
  9. In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y.A., Tyrrell, K.L., Fernandez, H.T. Antimicrob. Agents Chemother. (2002) [Pubmed]
  10. Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats. Kappel, E.M., Shakibaei, M., Bello, A., Stahlmann, R. Antimicrob. Agents Chemother. (2002) [Pubmed]
  11. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. Weller, T.M., Andrews, J.M., Jevons, G., Wise, R. J. Antimicrob. Chemother. (2002) [Pubmed]
  12. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Wise, R., Gee, T., Marshall, G., Andrews, J.M. Antimicrob. Agents Chemother. (2002) [Pubmed]
  13. Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits. Takahata, M., Yamada, H., Morita, T., Furubou, S., Minami, S., Todo, Y., Watanabe, Y., Narita, H. Antimicrob. Agents Chemother. (2002) [Pubmed]
  14. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Gradelski, E., Valera, L., Kolek, B., Bonner, D., Fung-Tomc, J. Int. J. Antimicrob. Agents (2001) [Pubmed]
  15. Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Cottagnoud, P., Acosta, F., Cottagnoud, M., Pfister, M., Täuber, M.G. Antimicrob. Agents Chemother. (2002) [Pubmed]
  16. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Takahata, M., Mitsuyama, J., Yamashiro, Y., Yonezawa, M., Araki, H., Todo, Y., Minami, S., Watanabe, Y., Narita, H. Antimicrob. Agents Chemother. (1999) [Pubmed]
  17. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. Reinert, R.R., Al-Lahham, A., Lütticken, R., Boos, M., Schmitz, F.J. J. Antimicrob. Chemother. (2002) [Pubmed]
  18. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. Edelstein, P.H., Shinzato, T., Edelstein, M.A. J. Antimicrob. Chemother. (2001) [Pubmed]
  19. Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756. Gajjar, D.A., Sukoneck, S.C., Bello, A., Ge, Z., Christopher, L., Grasela, D.M. Pharmacotherapy (2002) [Pubmed]
  20. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin. Clark, C.L., Nagai, K., Davies, T.A., Bozdogan, B., Dewasse, B., Jacobs, M.R., Appelbaum, P.C. Clin. Microbiol. Infect. (2002) [Pubmed]
  21. In vitro susceptibility testing of BMS-284756 by the BSAC standardized disc testing method. Andrews, J.M., Wise, R. J. Antimicrob. Chemother. (2001) [Pubmed]
  22. Determination of BMS-284756, a new quinolone, in mouse serum by high-performance liquid chromatography with fluorescence detection. Xuan, D., Turley, C., Nightingale, C.H., Nicolau, D.P. J. Chromatogr. B Biomed. Sci. Appl. (2001) [Pubmed]
WikiGenes - Universities